PHILADELPHIA, Nov. 8, 2007 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB - News) announced its interim financial results for the three months ended September 30, 2007. The net loss for this fiscal quarter was approximately $5,718,000 or $(.08) per share compared to a loss of $3,807,000 or $(.06) per share for the same period in 2006. The $1,911,000 increase in loss was basically due to higher general and administrative expense of $2,232,000, primarily related to non-cash equity-based compensation expense. The results also reflect increased research and development costs of approximately $228,000, primarily related to independent consultants used in preparing and filing the New Drug Application (NDA) for the experimental therapeutic Ampligen(r) (Poly I: Poly C12U) to treat Chronic Fatigue Syndrome (CFS), offset by lower interest and financing costs of approximately $295,000 related to reduced debt and debt discount amortization. In July, the Company announced the retirement of all remaining debt related to convertible debentures issued in 2003 and 2004.
